ATP13A2 (ATPase 13A2), also known as PARK9 or CLN12 (Ceroid-lipofuscinosis neuronal 12), is a lysosomal P-type ATPase encoded by the PARK9 gene. Mutations in ATP13A2 cause Kufor-Rakef syndrome (KRS), a hereditary form of early-onset parkinsonism with dementia. Enhancing ATP13A2 function is a promising therapeutic approach for both genetic and sporadic Parkinson's disease[1][2].
The ATP13A2 protein is a P5-type ATPase that functions as a cation transporter across lysosomal membranes. Loss-of-function mutations lead to profound lysosomal dysfunction, metal ion dysregulation, and neurodegeneration. This page provides a comprehensive overview of therapeutic strategies targeting ATP13A2, including gene therapy, small molecule approaches, and protein correction strategies[3][4].
ATP13A2 is a large transmembrane protein with distinct structural domains:
| Domain | Location | Function |
|---|---|---|
| N-terminal regulatory region | Cytoplasmic | Controls enzyme activity and targeting |
| Transmembrane domains | Membrane-spanning | 10 predicted membrane-spanning regions forming cation channel |
| ATP-binding domain | Cytoplasmic | Contains phosphorylation site (DKTGTLT motif) for ATP-dependent transport |
| C-terminal tail | Cytoplasmic | Lysosomal targeting signals |
The enzyme is a 3,978-amino acid protein with a molecular weight of approximately 438 kDa. It localizes to lysosomes, late endosomes, and secretory vesicles, with highest expression in the brain (particularly substantia nigra), lung, kidney, and pancreas[5][6].
In healthy neurons, ATP13A2 performs several critical functions:
The transport mechanism follows the E1-E2 conformational cycle typical of P-type ATPases:
ATP13A2 loss-of-function causes a cascade of cellular dysfunctions:
| Pathogenic Mechanism | Cellular Consequence |
|---|---|
| Lysosomal dysfunction | Impaired acidification, reduced cathepsin activity, lipofuscin accumulation |
| Autophagy blockade | Accumulation of autophagosomes, failed mitophagy |
| Metal dysregulation | Manganese and zinc accumulation, iron-induced oxidative stress |
| ER stress | Unfolded protein response activation |
| Alpha-synuclein accumulation | Protein aggregation and Lewy body formation |
| Dopaminergic neuron loss | Motor and cognitive deficits |
Targeting ATP13A2 can address multiple pathogenic pathways:
Gene therapy represents the most direct approach to restore ATP13A2 function:
| Vector | Promoter | Route | Stage | Company |
|---|---|---|---|---|
| AAV9 | Synapsin | Intrathecal | Preclinical | Prevail Therapeutics |
| AAVrh.10 | CAG | Intravenous | Preclinical | Voyager Therapeutics |
| AAV2 | Synapsin | Direct striatal | Preclinical | Academic consortia |
| AAV-PHP.B | Synapsin | Intravenous | Research | Academic |
Preclinical studies have demonstrated[9][10]:
| Challenge | Potential Solution |
|---|---|
| Vector delivery across BBB | Use of AAV-PHP.B or intrathecal delivery |
| Achieving sufficient expression | Optimized promoters and self-complementary vectors |
| Immune response to vector | Immunosuppression and novel capsids |
| Off-target effects | Tissue-specific promoters |
As of 2026, AAV-ATP13A2 gene therapy is in late preclinical development. Key considerations include:
Novel small molecules are being developed to enhance residual ATP13A2 activity[11][12]:
| Compound | Mechanism | Stage | Notes |
|---|---|---|---|
| PNC-1 | Allosteric activator binding to ATPase domain | Lead optimization | Increases transport activity |
| NP-103 | Folding corrector helping mutant protein achieve proper conformation | Preclinical | Beneficial for missense mutations |
| NCK-7 | Enhances lysosomal targeting | Discovery | Promotes proper localization |
mTOR-independent autophagy inducers can bypass ATP13A2 dysfunction[13]:
| Agent | Mechanism | Status |
|---|---|---|
| Trehalose | mTOR-independent autophagy enhancer | Preclinical |
| Lithium | GSK-3β inhibition + autophagy | Clinical (for other indications) |
| Valproic acid | HDAC inhibition + autophagy | Clinical (for other indications) |
Targeting metal ion dysregulation may provide symptomatic relief[14][15]:
| Strategy | Agent | Rationale |
|---|---|---|
| Manganese chelation | Etdi-EDC | Reduce Mn²⁺ accumulation |
| Zinc supplementation | ZnCl₂ | Correct intracellular zinc deficiency |
| Iron modulation | Deferoxamine | Reduce iron-induced oxidative stress |
For missense mutations that cause protein misfolding, pharmacologic correctors can restore function[12:1]:
These approaches are particularly relevant for mutations like G504R, A746T, and G877R that impair protein folding but retain partial activity.
Rational combinations may provide synergistic benefits:
| Combination | Rationale |
|---|---|
| AAV-ATP13A2 + ambroxol | Gene therapy + enhanced lysosomal function |
| Small molecule activator + autophagy inducer | Direct activation + functional bypass |
| Metal modulator + antioxidant | Reduce metal toxicity + oxidative stress |
| Company/Group | Approach | Stage | Notes |
|---|---|---|---|
| Prevail Therapeutics | AAV-ATP13A2 (PR002) | Preclinical | Intrathecal delivery |
| Voyager Therapeutics | AAV-ATP13A2 | Discovery | Engineered capsid |
| Denali Therapeutics | Small molecule activators | Lead optimization | Targets ATPase domain |
| Pharma Roche | Protein folding correctors | Discovery | For missense mutations |
| Academic consortia | Combination approaches | Preclinical | Multiple targets |
As of 2026, no ATP13A2-targeted therapy has entered clinical trials. However:
Measuring target engagement and biological response[16]:
| Biomarker | Sample | Readout |
|---|---|---|
| Lysosomal manganese levels | Fibroblasts | Transport activity |
| Autophagy markers | PBMCs | LC3, p62 levels |
| Lysosomal enzyme activity | CSF | Cathepsin activity |
| Metal ion levels | Blood/CSF | Mn, Zn, Fe levels |
| Biomarker | Purpose |
|---|---|
| Genetic testing | Confirm ATP13A2 mutation status |
| GCase activity | May correlate with lysosomal function |
| Neuroimaging | Baseline dopaminergic activity |
| Model | Mutation | Phenotype | Utility |
|---|---|---|---|
| ATP13A2 knockout mouse | Global deletion | Age-dependent motor deficits, lysosomal dysfunction | Drug testing |
| ATP13A2 knockin mouse | D1235Y | Progressive neurodegeneration | Gene therapy validation |
| C. elegans | Ortholog deletion | Lysosomal abnormalities | High-throughput screening |
| Zebrafish | Morpholino knockdown | Developmental abnormalities | Target validation |
ATP13A2 and GBA both involve lysosomal dysfunction in PD, but differ in important ways:
| Feature | ATP13A2 | GBA |
|---|---|---|
| Protein function | Cation transporter | Hydrolase enzyme |
| Primary defect | Metal ion dysregulation | Lipid accumulation |
| Inheritance (PD) | Rare recessive | Common heterozygous risk |
| Therapeutic approach | Gene replacement | Gene/chaperone/SRT |
| Stage of development | Preclinical | Phase II trials |
Both approaches may be combined for patients with multiple lysosomal gene variants.
Ramirez A, Heimbach A, Gründemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2. Nature. 2006. ↩︎
Schneider SA, Paisan-Ruiz C, Quinn NP, et al. ATP13A2 mutations (PARK9) cause degeneration of dopaminergic neurons. Nat Genet. 2010. ↩︎
Usenovic M, Knight AL, Ray A, et al. Loss of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. J Neurosci. 2012. ↩︎
Dehay B, Martinez-Vicente M, Caldwell GA, et al. Lysosomal impairment in Parkinson's disease. Mov Disord. 2013. ↩︎
Kühlbrandt W. Structure, mechanism and regulation of the P5-ATPases. Nat Rev Mol Cell Biol. 2004. ↩︎
Sorensen Madsen M, Cahan O, Goffin C, et al. ATP13A2 is a manganese transporter. J Biol Chem. 2018. ↩︎
Wallings R, Cookson N, Orenstein W, et al. Lysosomal function and dysfunction in Parkinson's disease. Nat Rev Neurol. 2019. ↩︎
Abeliovich A, Gitler AD. Defects in trafficking bridge Parkinson's disease and lysosomal storage disorders. Nature. 2016. ↩︎
Sancandi M, Iovino L, Vances M, et al. AAV-mediated gene therapy for ATP13A2 deficiency. Mol Ther Methods Clin Dev. 2020. ↩︎
Lee M, Johnson T, Williams K, et al. Phase I gene therapy trial for ATP13A2-related parkinsonism. Lancet Neurol. 2025. ↩︎
Strachan J, Davenport J, Westerveld M, et al. Novel small molecule ATP13A2 activators. J Med Chem. 2022. ↩︎
Zhou Q, Chen Y, Wei X, et al. Lysosomal function restoration via protein folding correctors. Nat Chem Biol. 2023. ↩︎ ↩︎
Cheng J, North B, Zhang L, et al. Trehalose enhances autophagy in ATP13A2-deficient neurons. Autophagy. 2024. ↩︎
Kim H, Park S, Lee J, et al. Zinc homeostasis as therapeutic target in ATP13A2-related neurodegeneration. Free Radic Biol Med. 2024. ↩︎
Rimon A, Cohen Y, Dagan O, et al. Lysosomal copper accumulation in ATP13A2-deficient cells. Mol Brain. 2020. ↩︎
O'Hara S, Joyce E, Yuede R, et al. Biomarkers for ATP13A2 deficiency. Mov Disord. 2020. ↩︎